All In Biotech

Investigational drug · Phase 3

Anlotinib hydrochloride

Also called: AL3818, Catequentenib

Not approved by FDA. In 12 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms.

Phase 3

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

12

12 still active

All registered trials

184

Any phase or sponsor naming "Anlotinib hydrochloride"

First trial start

2017

Aug 15, 2017

Conditions studied

As listed on its trial records.

  • Alveolar Soft Part Sarcoma
  • Metastatic Colorectal Cancer
  • Endometrial Neoplasms
  • Ovarian Neoplasms
  • Soft Tissue Sarcoma (STS)
  • Glioblastoma
  • Non-small Cell Lung Caner
  • KRAS-mutated
  • Metastasis
  • Previous Treamted

Approved drugs for the same conditions: Colorectal cancer · Endometrial cancer · Brain tumors (glioma) · Sarcoma · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "Anlotinib hydrochloride" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 56 on PubMed

Also in development for Alveolar Soft Part Sarcoma

  • BenmelstobartPhase 24 trials

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Alveolar Soft Part Sarcoma, Non-Small Cell Lung Cancer, Gastroesophageal Adenocarcinoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.